RICHMOND, VA: Insmed, a developer of follow-on biologics (FOBs) and biopharmaceuticals, has launched a broad education campaign in its hopes to raise awareness of the importance of establishing a regulatory pathway in the US for FOBs.
While a regulatory system for approving FOBs (a term to describe copies of new biopharmaceutical products) was established in Europe in 2006, the US has yet to follow suit. The company's aim, noted Steve Glover, president of Insmed Therapeutic Proteins, is to encourage Congress to ...